I’ve written about STAT’s Morning Rounds newsletter in the past, and criticized how STAT accepts pharma sponsorship of the newsletter.
In the last two weeks, for example, the newsletter has featured sponsored content from:
- drug company AstraZeneca;
- the Biotechnology Innovation Organization – whose biggest sponsors include drug companies Lilly, Merck, Amgen, Johnson & Johnson;
- biotech company Genentech;
- Blue Cross Blue Shield Association;
- drug company Bristol Myers Squibb.
I believe that an ethical news organization that covers pharma and biotech full-time should not accept sponsorship from pharma and biotech.
In Monday’s STAT Morning Rounds newsletter this week, there was this news item:
AstraZeneca announced over the weekend that it had struck a deal to provide up to 400 million doses of its experimental Covid-19 vaccine to countries in the European Union. The company plans to begin delivering the vaccine to European countries by the end of this year under an agreement with the Inclusive Vaccine Alliance, which was formed by France, Germany, Italy, and the Netherlands. Other EU countries will also have a chance to partake in the deal.
I clicked on the link. It didn’t take me to a news story or to any independently-vetted piece of journalism. Instead, the link went directly to an AstraZeneca PR news release.
That’s a nice piece of free news attention – if you can get it.
I looked for data in the AstraZeneca PR to which STAT had linked me. There was none. But there was this – presumably to satisfy the lawyers:
AstraZeneca recognises that the vaccine may not work but is committed to progressing the clinical programme with speed and scaling up manufacturing at risk.
That doesn’t satisfy me – and it shouldn’t satisfy STAT’s readers.
The news item – and the link – weren’t sponsored content and weren’t associated with an advertisement. We expect a leading news organization that specializes in health care news to offer news, not PR, with its links.
I recall how a leading health care journalist wrote to me about STAT’s coverage of the Gilead drug remdesivir on April 29. The journalist wrote:
I know that STAT’s business model is implicitly pro-pharma but even given that, this story is a press release.
In this latest case, there could be no doubt that the story was nothing about a press release.
So it’s double bonanza time for some drug companies and biotech firms on STAT. Pay for your sponsored content to be placed right in the middle of the morning news. And, if you’re lucky, get your PR news releases posted for free. Straight from the company’s keyboard to your eyes. I think we can and should do better in covering coronavirus vaccine news.
more recommended stories
You Can See Friends and Relatives During the Pandemic Surge — But Do It Carefully
Cooped up too long, yearning for.
Families Of Health Workers Killed By COVID Fight For Denied Workers’ Comp Benefits
James “Mike” Anderson was a hospital.
As COVID Testing Soars, Wait Times For Results Jump To A Week — Or More
Elliot Truslow went to a CVS.
Shingles Vaccination Rate Soars But Leaves Many Behind
Worried about the high cost of.
Analysis: How A COVID-19 Vaccine Could Cost Americans Dearly
Yes, of course, Americans’ health is.
Coronavirus Crisis Disrupts Treatment For Another Epidemic: Addiction
Shawn Hayes was thankful to be.
Some global reaction to the news of US mass purchase of remdesivir
Canadian physician-researcher James Brophy of McGill.
Coronavirus Briefing: Reopening goes awry, Remdesivir’s price tag and the point-of-care pivot
When COVID-19 first announced its presence.
Warning: early vaccine trial results don’t always stand test of time
“The drugmaker Moderna said on Monday.
As Cases Spike, California Pauses Multimillion-Dollar Testing Expansion
In April, Gov. Gavin Newsom launched.